On Friday, Shares of Whiting Petroleum Corp (NYSE:WLL), subtract -1.92% and closed at $8.68 in the last trading session. The last trading range of the stock ranges between $8.62 and $8.99. Whiting Petroleum Corporation (NYSE:WLL) will release its third quarter 2016 financial and operating results on Wednesday, October 26, 2016 after the market closes. A conference call with shareholders, analysts and other interested parties is planned for 11:00 a.m. EDT (10:00 a.m. CDT, 9:00 a.m. MDT) on Thursday, October 27, 2016 to discuss Whiting’s third quarter 2016 financial and operating results.
A telephonic replay will be available starting one to two hours after the call on Thursday, October 27, 2016 and continuing through Thursday, November 3, 2016. You may access this replay at (877) 344-7529 (U.S.), (855) 669-9658 (Canada) or (412) 317-0088 (International) and enter the replay access code 10093213.
Kinder Morgan Inc (NYSE:KMI), dropped -0.92% and closed at $20.36 in the last trading session. The last trading range of the stock ranges between $20.36 and $21.06. The company’s Market capitalization is $45.03 Billion with the total Outstanding Shares of 2.23 billion. Kinder Morgan, Inc. operates as an energy infrastructure company in North America. It operates through Natural Gas Pipelines, CO2, Terminals, Products Pipelines, Kinder Morgan Canada, and Other segments. The Natural Gas Pipelines segment owns and operates interstate and intrastate natural gas pipeline and storage systems; natural gas and crude oil gathering systems, and natural gas processing and treating facilities; natural gas liquids fractionation facilities and transportation systems; and liquefied natural gas facilities. The CO2 segment produces, transports, and markets CO2 for use in improved oil recovery projects; and owns interests in oil-producing fields, gas processing plants, and crude oil pipelines in the Permian Basin region of West Texas. The Terminals segment owns and operates liquids and bulk terminals that transload and store refined petroleum products, crude oil, and condensate, in addition to bulk products, counting coal, petroleum coke, cement, alumina, salt, and other bulk chemicals; and owns and operates tankers. The Products Pipelines segment owns and operates refined petroleum products, and crude oil and condensate pipelines; and associated product terminals and petroleum pipeline transmix facilities. The Kinder Morgan Canada segment owns and operates Trans Mountain pipeline system that transports crude oil and refined petroleum products from Edmonton, Alberta, and Canada to marketing terminals and refineries in British Columbia, Canada, and Washington; and jet fuel aviation turbine fuel pipeline that serves the Vancouver (Canada) International Airport. The Other segment includes various physical natural gas contracts with power plants. Kinder Morgan, Inc. owns interests in or operates about 84,000 miles of pipelines and 180 terminals.
Pfizer Inc. (NYSE:PFE), lost -0.31% and closed at $32.66 in the last trading session. The last trading range of the stock ranges between $32.66 and $32.99. The company’s Market capitalization is $197.50 Billion with the total Outstanding Shares of 6.07 billion. During the 52-week trading session the minimum price at which share price traded, registered at $28.25 and reached to max level of $37.39. Pfizer Inc. (PFE) declared that three abstracts for XELJANZ® (tofacitinib citrate), being investigated in moderate to severe ulcerative colitis (UC), will be presented at the forthcoming United European Gastroenterology Week (UEG Week 2016), October 15-19 in Vienna, Austria. The tofacitinib presentations will highlight new research results from the Phase 3 Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) Induction trials, counting one oral presentation looking at the effect of prior treatment with tumor necrosis factor inhibitors (TNFi) on efficacy endpoints. In addition, two abstracts have been accepted as poster presentations, highlighting results by endoscopic response, and onset of action, respectively.
“The new data to be presented at UEG Week deepen our understanding of the efficacy and safety profile of tofacitinib in ulcerative colitis,” said Michael Corbo, PhD, Chief Development Officer, Inflammation & Immunology, Pfizer Inc. “We know there is a noteworthyunmet need in the UC community for additional treatment options and, if approved, tofacitinib may have the potential to offer patients and their physicians an oral treatment option that could address these unmet needs in the course of the disease.”